Checkpoint inhibitors do one thing: release the molecular brake that keeps immune cells from recognizing and targeting tumors. This cancer immunotherapy approach has saved countless lives and turned drugs from Merck and Bristol Myers Squibb into blockbuster products.
But what if a single drug could block checkpoint proteins while simultaneously sparking an anti-tumor response? That’s what Shattuck Labs aims to do. Its lead asset is in development under a partnership with Takeda Pharmaceutical (NYSE: TAK), and now the biotech has $118 million more to advance additional compounds to human testing. The Series B round of financing announced this week was… Read more »
UNDERWRITERS AND PARTNERS